沃森生物：拟3.60亿元受让控股子公司2.4793%股权

Core Viewpoint - Watson Bio announced the acquisition of a 2.4793% stake in its subsidiary Yuxi Watson from Tianjin Lanwo for a price of 359.4985 million yuan, which is expected to enhance control over Yuxi Watson and positively impact the company's performance for the current year, although there are uncertainties involved [1] Financial Summary - Yuxi Watson's projected revenue for 2024 is 2.664 billion yuan and net profit is 254 million yuan [1] - For the first nine months of 2025, Yuxi Watson reported revenue of 1.682 billion yuan and net profit of 269 million yuan [1] Transaction Details - The board meeting for the acquisition is scheduled for November 28, 2025, with payment due by November 30, 2025, and formal transfer of shares upon completion of business registration [1]